Cataract incision size is just right thanks to new technology

Article

Incision sizes needed to remove cataracts have been significantly reduced by new technology, such as the vision enhancement system (Stellaris; Bausch & Lomb) which allows surgeons to make two 1.8 mm cuts on either side of the eye.

Incision sizes needed to remove cataracts have been significantly reduced by new technology, such as the vision enhancement system (Stellaris; Bausch & Lomb) which allows surgeons to make two 1.8 mm cuts on either side of the eye.

Now that the device has been used as part of clinical trials in a number of hospitals it is being sold to NHS trusts in the UK for £70,000 (around €92,000). The machine guides surgeons to make the right incisions, and the clouded lens is broken up using ultrasound before it is extracted. A new folded lens is injected into the space, where it is unfurled.

"It's a very quick and efficient procedure, it's painless, [with] no stitches, and [patients] can get up and walk out straight afterwards without the need for a patch and little danger of infection," said Sheraz Daya, MD, a consultant ophthalmologist at Queen Victoria Hospital, West Sussex, UK.

Other consultants agreed with Dr Daya's assessment, although they stressed that Stellaris was not the only device capable of reducing the incision to 1.8 mm. At least two other phaco systems (Sovereign; Advanced Medical Optics & Infiniti; Alcon Laboratories) are available.

"All these technologies are a move in the right direction," said Larry Benjamin, DO, an eye surgeon at Stoke Mandeville Hospital, Buckinghamshire, UK. "Smaller cuts are better, while the mechanism keeps the eye steady. The only problem is many of the lenses on the market aren't yet small enough to fit through this kind of incision, so one side of the technology has yet to catch up with the other."

Recent Videos
David Yorston, FRCS, FRCOphth, discusses his EURETINA keynote lecture
Hoda Shamsnajafabadi, MSc, PhD, presents at the 2024 EURETINA meeting
Timothy L Jackson PhD, MB ChB, FRCOphth, speaks about a combination therapy for VEGF-A/C/D inhibition with sozinibercept and ranibizumab
Carl Awh, MD, FASRS, speaks about the American Society of Retina Specialists (ASRS) at EURETINA
Stefano Mercuri, MD, first author of the winning eposter “Genotype-phenotype correlations in a cohort of genetically determined Retinitis Pigmentosa (RP) Italian patients with Rho gene mutations”
Bahram Bodaghi, MD, PHD, FEBO at the 2024 EURETINA meeting
Enrico Borrelli, MD, FEBO, speaks at EURETINA
Aleksandra Rachitskaya, MD, FASRS, speaks about the Vit-Buckle Society at the 2024 EURETINA Congress.
© 2024 MJH Life Sciences

All rights reserved.